San Francisco-based health tech startup Nucs AI, which uses AI to deliver personalized prostate cancer tumor analysis for improved treatment decisions, has raised $3.5 million in a seed funding round. The investors in the round remain undisclosed.
- Founded in 2023 by Nijat Ahmadov and Farid Yagubbayli, Nucs AI focuses on developing an AI-powered platform to assist healthcare professionals in managing prostate cancer.
- The platform leverages advanced AI to analyze patient imaging data, such as PSMA-PET/CT scans, to assess tumor characteristics and predict outcomes.
- Nucs AI enhances doctors' decision-making process by providing tools like DeepPSMA, which quantifies tumor burden, and SelectPSMA, which predicts the effectiveness of PSMA-targeted treatments.
- The platform works in three steps: healthcare providers upload imaging data, AI analyzes it to quantify tumor burden and treatment response, and Nucs AI generates personalized reports to guide treatment decisions.
"Our DeepPSMA product uses discriminative AI to enable fast and reliable detection, staging, and quantification of prostate cancer based on the PSMA-PET/CT images and SelectPSMA identifies those who will respond to PSMA targeted radiopharmaceuticals," Nucs AI's team, commented on LinkedIn.
- With the fresh capital, the startup will enhance its AI platform, scale operations, expand R&D, and grow its team to drive innovation and adoption in healthcare.
"The funding will be vital to support our mission of arming physicians with better tools to diagnose and treat prostate cancer, which afflicts 1.5 million men globally," Nucs AI's team, commented on LinkedIn.
